Cell & gene therapy

Despite their potential to change the face of medicine, reducing long-term medical costs and curing diseases, innovations in cell and gene therapy face regulatory issues, along with the need for long-term studies, before market acceptance can be achieved.  

Research in this important field is undergoing rapid growth. However, due to the significant costs and timescales involved in gaining approval, effective IP strategies must be established to protect investment and maintain market position. 

Working across academic research institutes, SMEs and large multinationals, HGF’s specialist cell and gene therapy attorneys tap into their vast experience to develop robust and tailored IP strategies for their clients in this field. The team has extensive experience in helping organisations protect and exploit their IP and assess their freedom to operate.

Latest updates

UPC moves one step closer to 2022 launch

The Austrian parliament has completed the legislative procedure to ratify the Protocol on the provisional application of the Agreement on a Unified Patent Court (the “Protocol”; see here). When deposited, …

Read article
Event - 9th December 2021

Technology Transfer Primer - IP Management: AI and 5G in healthcare

The University of Hong Kong is hosting a webinar on ‘IP Management: AI and 5G in healthcare’ on 9th December 2021 with HGF’s Partner Dr Chris Benson and Patent Director …

Event details

Next Pro-Chancellor appointed at the University of Leeds

A Leeds alumnus has been appointed as the next Pro-Chancellor of the University of Leeds. A lawyer by background, with a strong track record in leadership in education and social …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our cell & gene therapy specialists.